Search results
Results from the WOW.Com Content Network
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, [8] which is used in the treatment of schizophrenia and bipolar disorder. [9] It is also prescribed as an add-on treatment for bipolar depression [ 10 ] and major depressive disorder . [ 6 ]
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
Misalignments of the body's circadian pacemaker with the environment (e.g., jet lag, shift work, or other circadian rhythm sleep disorders) [7] Another underlying sleep disorder, such as narcolepsy, sleep apnea, [8] idiopathic hypersomnia, or restless legs syndrome; Disorders such as clinical depression or atypical depression [medical citation ...
The labeling information of the treatment, Cobenfy, does not include a warning about the risk of increased mortality in some elderly patients, unlike other commonly used drugs for the disorder.
Sleep specialists measure the patient's sleep onset and offset, dim light melatonin onset, and evaluate Horne-Ostberg morningness-eveningness questionnaire results. Sleep specialists may also conduct a polysomnography test to rule out other sleep disorders like narcolepsy. Age and family history of the patient is also taken into consideration. [2]
The first book on sleep [citation needed] was published in 1830 by Robert MacNish; it described sleeplessness, nightmares, sleepwalking and sleep-talking. Narcolepsy, hypnogogic hallucination, wakefulness and somnolence were mentioned by other authors of the nineteenth century.
Still, the spokesperson said, it will work with the incoming administration to "deliver meaningful solutions for patients." About 5.3 million people on Medicare used the drugs between Nov. 1, 2023 ...
Empirical evidence, combined with treatment considerations, led the DSM-IV Mood Disorders Work Group to add BP-II as its own entity in the 1994 publication. Only one other mood disorder was added to this edition, indicating the conservative nature of the DSM-IV work group. In May 2013, the DSM-5 was released. Two revisions to the existing BP-II ...